Ibrutinib and Paxlovid (Nirmatrelvir/Ritonavir) (Paxlovid 150 mg/100 mg Film Kaplı Tablet): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Ritonavir strongly inhibits CYP3A and can increase ibrutinib exposure.
Clinical significance and safety
The current Paxlovid prescribing information recommends avoiding use with ibrutinib. For Ibrutinib with Paxlovid (Nirmatrelvir/Ritonavir), the cancer and COVID-19 treatment teams should coordinate an alternative antiviral or an appropriate specialist treatment plan. Do not stop cancer treatment or change the doses yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.